Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001398373 | SCV001600142 | likely benign | Neuroblastoma, susceptibility to, 3 | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002449092 | SCV002732021 | likely benign | Hereditary cancer-predisposing syndrome | 2022-09-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003920874 | SCV004733071 | likely benign | ALK-related disorder | 2022-12-21 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |